Terms: = Germ cell tumor AND CTLA4, ALPS5, CD, CD152, CELIAC3, CTLA-4, GRD4, GSE, IDDM12 AND Clinical Outcome
49 results:
1. B7-H3 is associated with the armored-cold phenotype and predicts poor immune checkpoint blockade response in melanoma.
Shen B; Mei J; Xu R; Cai Y; Wan M; Zhou J; Ding J; Zhu Y
Pathol Res Pract; 2024 Apr; 256():155267. PubMed ID: 38520953
[TBL] [Abstract] [Full Text] [Related]
2. IFN-γ Triggered IFITM2 Expression to Induce Malignant Phenotype in Elderly GBM.
Liang T; Wang X; Wang Y; Ma W
J Mol Neurosci; 2023 Dec; 73(11-12):946-955. PubMed ID: 37889394
[TBL] [Abstract] [Full Text] [Related]
3. Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial.
Noviello TMR; Di Giacomo AM; Caruso FP; Covre A; Mortarini R; Scala G; Costa MC; Coral S; Fridman WH; Sautès-Fridman C; Brich S; Pruneri G; Simonetti E; Lofiego MF; Tufano R; Bedognetti D; Anichini A; Maio M; Ceccarelli M
Nat Commun; 2023 Sep; 14(1):5914. PubMed ID: 37739939
[TBL] [Abstract] [Full Text] [Related]
4. Prognostic significance of PD-1, ctla-4, CD4, and CD8 expression in olfactory neuroblastoma.
Wu L; Liu H; Liu H
Clin Neuropathol; 2023; 42(2):47-53. PubMed ID: 36708210
[TBL] [Abstract] [Full Text] [Related]
5. High Expression of the Lysosomal Protease Cathepsin D Confers Better Prognosis in Neuroblastoma Patients by Contrasting EGF-Induced Neuroblastoma cell Growth.
Secomandi E; Salwa A; Vidoni C; Ferraresi A; Follo C; Isidoro C
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563171
[TBL] [Abstract] [Full Text] [Related]
6. A One-Armed Phase I Dose Escalation Trial Design: Personalized Vaccination with IKKβ-Matured, RNA-Loaded Dendritic cells for Metastatic Uveal Melanoma.
Koch EAT; Schaft N; Kummer M; Berking C; Schuler G; Hasumi K; Dörrie J; Schuler-Thurner B
Front Immunol; 2022; 13():785231. PubMed ID: 35185883
[TBL] [Abstract] [Full Text] [Related]
7. Multiparametric MRI of early tumor response to immune checkpoint blockade in metastatic melanoma.
Lau D; McLean MA; Priest AN; Gill AB; Scott F; Patterson I; Carmo B; Riemer F; Kaggie JD; Frary A; Milne D; Booth C; Lewis A; Sulikowski M; Brown L; Lapointe JM; Aloj L; Graves MJ; Brindle KM; Corrie PG; Gallagher FA
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34561275
[TBL] [Abstract] [Full Text] [Related]
8. Inflammatory B cells correlate with failure to checkpoint blockade in melanoma patients.
de Jonge K; Tillé L; Lourenco J; Maby-El Hajjami H; Nassiri S; Racle J; Gfeller D; Delorenzi M; Verdeil G; Baumgaertner P; Speiser DE
Oncoimmunology; 2021 Feb; 10(1):1873585. PubMed ID: 33643691
[TBL] [Abstract] [Full Text] [Related]
9. DZIP3 is a key factor to stratify IDH1 wild-type lower-grade gliomas.
Liang T; Zhou X; Li P; You G; Wang F; Wang P; Feng E
Aging (Albany NY); 2020 Nov; 12(24):24995-25004. PubMed ID: 33229627
[TBL] [Abstract] [Full Text] [Related]
10. A novel immune checkpoint-related seven-gene signature for predicting prognosis and immunotherapy response in melanoma.
Tian M; Yang J; Han J; He J; Liao W
Int Immunopharmacol; 2020 Oct; 87():106821. PubMed ID: 32731180
[TBL] [Abstract] [Full Text] [Related]
11. CD96, a new immune checkpoint, correlates with immune profile and clinical outcome of glioma.
Liu F; Huang J; He F; Ma X; Fan F; Meng M; Zhuo Y; Zhang L
Sci Rep; 2020 Jul; 10(1):10768. PubMed ID: 32612110
[TBL] [Abstract] [Full Text] [Related]
12. The therapeutic potential of targeting CD73 and CD73-derived adenosine in melanoma.
Soleimani A; Farshchi HK; Mirzavi F; Zamani P; Ghaderi A; Amini Y; Khorrami S; Mashayekhi K; Jaafari MR
Biochimie; 2020 Sep; 176():21-30. PubMed ID: 32585229
[TBL] [Abstract] [Full Text] [Related]
13. Anti-PD-1/L1-associated immune-related adverse events as harbinger of favorable clinical outcome: systematic review and meta-analysis.
Park R; Lopes L; Saeed A
Clin Transl Oncol; 2021 Jan; 23(1):100-109. PubMed ID: 32495269
[TBL] [Abstract] [Full Text] [Related]
14. Impact of a preceding radiotherapy on the outcome of immune checkpoint inhibition in metastatic melanoma: a multicenter retrospective cohort study of the DeCOG.
Knispel S; Stang A; Zimmer L; Lax H; Gutzmer R; Heinzerling L; Weishaupt C; Pföhler C; Gesierich A; Herbst R; Kaehler KC; Weide B; Berking C; Loquai C; Utikal J; Terheyden P; Kaatz M; Schlaak M; Kreuter A; Ulrich J; Mohr P; Dippel E; Livingstone E; Becker JC; Weichenthal M; Chorti E; Gronewold J; Schadendorf D; Ugurel S
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32371460
[TBL] [Abstract] [Full Text] [Related]
15. A Case of Acute Exacerbation of Chronic Adrenal Insufficiency Due to Ipilimumab Treatment for Advanced Melanoma.
Sakaguchi C; Yano S; Ashida K; Wada N; Ohe K; Nagata H; Matsuda Y; Sakamoto S; Sakamoto R; Ohnaka K; Uchi H; Furue M; Nomura M; Ogawa Y
Am J Case Rep; 2019 Jan; 20():106-110. PubMed ID: 30679413
[TBL] [Abstract] [Full Text] [Related]
16. Pineal Cyst-Related Aqueductal Stenosis as Cause of Intractable Headaches in Nonhydrocephalic Patients.
Pitskhelauri DI; Konovalov AN; Abramov IT; Danilov GV; Pronin IN; Alexandrova EV; Serova NK; Sanikidze AZ
World Neurosurg; 2019 Mar; 123():e147-e155. PubMed ID: 30468924
[TBL] [Abstract] [Full Text] [Related]
17. Soluble ctla-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study.
Pistillo MP; Fontana V; Morabito A; Dozin B; Laurent S; Carosio R; Banelli B; Ferrero F; Spano L; Tanda E; Ferrucci PF; Martinoli C; Cocorocchio E; Guida M; Tommasi S; De Galitiis F; Pagani E; Antonini Cappellini GC; Marchetti P; Quaglino P; Fava P; Osella-Abate S; Ascierto PA; Capone M; Simeone E; Romani M; Spagnolo F; Queirolo P;
Cancer Immunol Immunother; 2019 Jan; 68(1):97-107. PubMed ID: 30311027
[TBL] [Abstract] [Full Text] [Related]
18. Long term impact of ctla4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma.
Retseck J; Nasr A; Lin Y; Lin H; Mendiratta P; Butterfield LH; Tarhini AA
J Transl Med; 2018 Jul; 16(1):184. PubMed ID: 29973204
[TBL] [Abstract] [Full Text] [Related]
19. Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-ctla4, and Biomarkers to Predict clinical outcome.
Forget MA; Haymaker C; Hess KR; Meng YJ; Creasy C; Karpinets T; Fulbright OJ; Roszik J; Woodman SE; Kim YU; Sakellariou-Thompson D; Bhatta A; Wahl A; Flores E; Thorsen ST; Tavera RJ; Ramachandran R; Gonzalez AM; Toth CL; Wardell S; Mansaray R; Patel V; Carpio DJ; Vaughn C; Farinas CM; Velasquez PG; Hwu WJ; Patel SP; Davies MA; Diab A; Glitza IC; Tawbi H; Wong MK; Cain S; Ross MI; Lee JE; Gershenwald JE; Lucci A; Royal R; Cormier JN; Wargo JA; Radvanyi LG; Torres-Cabala CA; Beroukhim R; Hwu P; Amaria RN; Bernatchez C
Clin Cancer Res; 2018 Sep; 24(18):4416-4428. PubMed ID: 29848573
[No Abstract] [Full Text] [Related]
20. Cancer-germline Antigen Expression Discriminates clinical outcome to ctla-4 Blockade.
Shukla SA; Bachireddy P; Schilling B; Galonska C; Zhan Q; Bango C; Langer R; Lee PC; Gusenleitner D; Keskin DB; Babadi M; Mohammad A; Gnirke A; Clement K; Cartun ZJ; Van Allen EM; Miao D; Huang Y; Snyder A; Merghoub T; Wolchok JD; Garraway LA; Meissner A; Weber JS; Hacohen N; Neuberg D; Potts PR; Murphy GF; Lian CG; Schadendorf D; Hodi FS; Wu CJ
Cell; 2018 Apr; 173(3):624-633.e8. PubMed ID: 29656892
[TBL] [Abstract] [Full Text] [Related]
[Next]
